Yervoy ipilimumab regulatory update

Germany's Federal Joint Committee (G-BA) said Yervoy from Bristol-Myers Squibb provides an "important additional benefit" over best supportive care in patients with advanced malignant melanoma who have received previous therapy. Best supportive care consists of the best individualized care to mitigate symptoms and improve quality of life. The final assessment is in line with a preliminary assessment from the Institute for Quality and Efficiency in Health Care (IQWiG). Bristol-Myers will now negotiate a price for Yervoy with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) (see BioCentury, May 7). ...